Lp-PLA2 and cardiovascular risk
| Study | Measure | Relative risk (95% CI) |
|---|---|---|
| CHD, coronary heart disease. | ||
| *Lowest quartile as reference; †lowest tertile as reference; ‡increase by 1SD of Lp-PLA2 activity. | ||
| Kardys et al23 | Measures of extracoronary atherosclerosis | 1.86 (1.01 to 3.43) in men |
| 1.60 (1.08 to 2.37) in women | ||
| Ballantyne et al24 | Ischaemic stroke | 1.91 (1.15 to 3.18)† |
| Khuseyinova et al25 | Coronary artery disease | 2.04 (1.19 to 3.48)* |
| Oei et al26 | CHD | 1.97 (1.28 to 3.02)* |
| Stroke | 1.97 (1.03 to 3.79)* | |
| Packard et al8 | CHD, death, myocardial infarction, revascularisation | 1.18 (1.05 to 1.33)‡ |
| Blake et al9 | CHD, death, myocardial infarction, stroke | 1.17 (0.45 to 3.05)* |
| Koening et al27 | CHD, death, myocardial infarction | 1.21 (1.01 to 1.45)‡ |
| Ballantyne et al10 | CHD, death, myocardial infarction, revascularisation | 1.15 (0.81 to 1.63)† |